|
Market Closed -
Nasdaq
16:00:00 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 417.84 USD | +0.40% |
|
+3.21% | +27.66% |
| 08-13 | Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating | MT |
| 08-13 | Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1,088B | - | - | - | - | - |
| 629B | - | - | - | - | - |
| 440B | - | - | - | - | - |
| 359B | - | - | - | - | - |
| 291B | - | - | - | - | - |
- Stock Market
- Stocks
- AMGN Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
